Tadaaki Yamada

List of Publications by Year
in descending order

155 papers	3,803 citations	117571 34 h-index	149623 56 g-index
156 all docs	156 docs citations	156 times ranked	5245 citing authors

#	Article	IF	Citations
1	Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Clinical Cancer Research, 2009, 15, 6630-6638.	3.2	255
2	AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells. Nature Communications, 2019, 10, 259.	5.8	223
3	Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort. Journal of Thoracic Oncology, 2011, 6, 2011-2017.	0.5	196
4	EGFR-TKI Resistance Due to BIM Polymorphism Can Be Circumvented in Combination with HDAC Inhibition. Cancer Research, 2013, 73, 2428-2434.	0.4	151
5	Paracrine Receptor Activation by Microenvironment Triggers Bypass Survival Signals and ALK Inhibitor Resistance in EML4-ALK Lung Cancer Cells. Clinical Cancer Research, 2012, 18, 3592-3602.	3.2	104
6	Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review. Journal of Clinical Medicine, 2020, 9, 1362.	1.0	102
7	Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-Mediated Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer. Clinical Cancer Research, 2011, 17, 2260-2269.	3.2	101
8	Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer. Clinical Cancer Research, 2010, 16, 174-183.	3.2	93
9	Tumor Neovascularization and Developments in Therapeutics. Cancers, 2019, 11, 316.	1.7	85
10	Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFRâ€mutated nonâ€small cell lung cancer. Cancer Medicine, 2019, 8, 1521-1529.	1.3	82
11	Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer. Molecular Cancer Therapeutics, 2012, 11, 2149-2157.	1.9	81
12	Met Kinase Inhibitor E7050 Reverses Three Different Mechanisms of Hepatocyte Growth Factorâ€"Induced Tyrosine Kinase Inhibitor Resistance in EGFR Mutant Lung Cancer. Clinical Cancer Research, 2012, 18, 1663-1671.	3.2	81
13	Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status. Cancer Research, 2019, 79, 1658-1670.	0.4	79
14	ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment inEGFR-Mutated Nonâ€"Small Cell Lung Cancer. Clinical Cancer Research, 2020, 26, 2244-2256.	3.2	75
15	Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer. Journal of Clinical Medicine, 2019, 8, 450.	1.0	72
16	Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphismâ€"Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer. Clinical Cancer Research, 2017, 23, 3139-3149.	3.2	69
17	Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer. Nature Communications, 2020, 11, 4607.	5.8	69
18	Ligandâ€triggered resistance to molecular targeted drugs in lung cancer: Roles of hepatocyte growth factor and epidermal growth factor receptor ligands. Cancer Science, 2012, 103, 1189-1194.	1.7	64

#	Article	IF	Citations
19	Notch3-dependent Î²-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC. Nature Communications, 2018, 9, 3198.	5.8	61
20	Overexpression of manganese superoxide dismutase by N-acetylcysteine in hyperoxic lung injury. Respiratory Medicine, 2007, 101, 800-807.	1.3	57
21	High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells. Oncotarget, 2016, 7, 3847-3856.	0.8	56
22	E7080, a Multiâ€“Tyrosine Kinase Inhibitor, Suppresses the Progression of Malignant Pleural Mesothelioma with Different Proangiogenic Cytokine Production Profiles. Clinical Cancer Research, 2009, 15, 7229-7237.	3.2	55
23	Dual Inhibition of Met Kinase and Angiogenesis to Overcome HGF-Induced EGFR-TKI Resistance in EGFR Mutant Lung Cancer. American Journal of Pathology, 2012, 181, 1034-1043.	1.9	55
24	Pleural Mesothelioma Instigates Tumor-Associated Fibroblasts To Promote Progression via a Malignant Cytokine Network. American Journal of Pathology, 2011, 179, 1483-1493.	1.9	54
25	MET Copy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis of EGFR-mutant Lung Cancer. Molecular Cancer Therapeutics, 2017, 16, 506-515.	1.9	52
26	The role of the gut microbiome on the efficacy of immune checkpoint inhibitors in Japanese responder patients with advanced non-small cell lung cancer. Translational Lung Cancer Research, 2019, 8, 847-853.	1.3	52
27	The EGFR Ligands Amphiregulin and Heparin-Binding EGF-like Growth Factor Promote Peritoneal Carcinomatosis in CXCR4-Expressing Gastric Cancer. Clinical Cancer Research, 2011, 17, 3619-3630.	3.2	46
28	Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells. Oncotarget, 2014, 5, 4920-4928.	0.8	46
29	Retrospective Efficacy Analysis of Immune Checkpoint Inhibitor Rechallenge in Patients with Non-Small Cell Lung Cancer. Journal of Clinical Medicine, 2020, 9, 102.	1.0	42
30	Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors. PLoS ONE, 2013, 8, e84700.	1.1	41
31	Hepatocyte Growth Factor Induces Resistance to Anti-Epidermal Growth Factor Receptor Antibody in Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 272-280.	0.5	37
32	Histone Deacetylase Inhibition Enhances the Antitumor Activity of a MEK Inhibitor in Lung Cancer Cells Harboring RAS Mutations. Molecular Cancer Therapeutics, 2018, 17, 17-25.	1.9	37
33	Hsp90 Inhibition Overcomes HGF-Triggering Resistance to EGFR-TKIs in EGFR-Mutant Lung Cancer by Decreasing Client Protein Expression and Angiogenesis. Journal of Thoracic Oncology, 2012, 7, 1078-1085.	0.5	34
34	Triple Inhibition of EGFR, Met, and VEGF Suppresses Regrowth of HGF-Triggered, Erlotinib-Resistant Lung Cancer Harboring an EGFR Mutation. Journal of Thoracic Oncology, 2014, 9, 775-783.	0.5	34
35	Safety and Usefulness of Cryobiopsy and Stamp Cytology for the Diagnosis of Peripheral Pulmonary Lesions. Cancers, 2019, 11, 410.	1.7	34
36	mTOR Inhibitors Control the Growth of EGFR Mutant Lung Cancer Even after Acquiring Resistance by HGF. PLoS ONE, 2013, 8, e62104.	1.1	32

#	Article	IF	Citations
37	Genetically engineered humanized antiâ€ganglioside GM2 antibody against multiple organ metastasis produced by GM2â€expressing smallâ€cell lung cancer cells. Cancer Science, 2011, 102, 2157-2163.	1.7	31
38	Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer. Lung Cancer, 2021, 161, 26-33.	0.9	31
39	Thioredoxin-1 protects against hyperoxia-induced apoptosis in cells of the alveolar walls. Pulmonary Pharmacology and Therapeutics, 2007, 20, 650-659.	1.1	29
40	TGF-Î²-dependent reprogramming of amino acid metabolism induces epithelialâ€“mesenchymal transition in non-small cell lung cancers. Communications Biology, 2021, 4, 782.	2.0	29
41	The novel phosphoinositide 3â€kinaseâ€“mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor. International Journal of Cancer, 2013, 133, 505-513.	2.3	28
42	Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinibâ€resistance of <scp>EML</scp>4â€<scp>ALK</scp> lung cancer and circumvention by epidermal growth factor receptor inhibitors. Cancer Science, 2017, 108, 53-60.	1.7	28
43	Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement. Cancer Letters, 2008, 265, 55-66.	3.2	26
44	A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma. Cancer Research, 2017, 77, 153-163.	0.4	26
45	Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusionâ€“Positive Tumor Cells in a Brain Metastasis Model. Clinical Cancer Research, 2018, 24, 2357-2369.	3.2	25
46	Significance of inflammatory indexes in atezolizumab monotherapy outcomes in previously treated non-small-cell lung cancer patients. Scientific Reports, 2020, 10, 17495.	1.6	24
47	Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations. Oncogene, 2013, 32, 4427-4435.	2.6	23
48	Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study. OncoImmunology, 2021, 10, 1950411.	2.1	22
49	Lysophosphatidic acid stimulates the proliferation and motility of malignant pleural mesothelioma cells through lysophosphatidic acid receptors, LPA₁ and LPA₂. Cancer Science, 2008, 99, 1603-1610.	1.7	20
50	Intensification therapy with anti-parathyroid hormone-related protein antibody plus zoledronic acid for bone metastases of small cell lung cancer cells in severe combined immunodeficient mice. Molecular Cancer Therapeutics, 2009, 8, 119-126.	1.9	20
51	Impact of <scp>MET</scp> inhibition on smallâ€cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/<scp>MET</scp> pathway. Cancer Science, 2017, 108, 1378-1385.	1.7	20
52	Paracrine activation of MET promotes peritoneal carcinomatosis in scirrhous gastric cancer. Cancer Science, 2013, 104, 1640-1646.	1.7	19
53	Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients. Translational Lung Cancer Research, 2019, 8, 450-460.	1.3	18
54	Carcinoembryonic antigen and CYFRA 21-1 responses as prognostic factors in advanced non-small cell lung cancer. Translational Lung Cancer Research, 2019, 8, 227-234.	1.3	17

#	Article	IF	Citations
55	Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M-Positive Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II Trial. Oncologist, 2019, 24, 593-e170.	1.9	17
56	The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2019, 14, 1061-1076.	0.5	17
57	Immune-Related Adverse Events Are Associated With Clinical Benefit in Patients With Non-Small-Cell Lung Cancer Treated With Immunotherapy Plus Chemotherapy: A Retrospective Study. Frontiers in Oncology, 2021, 11, 630136.	1.3	17
58	Prognostic Nutritional Index and Lung Immune Prognostic Index as Prognostic Predictors for Combination Therapies of Immune Checkpoint Inhibitors and Cytotoxic Anticancer Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer. Diagnostics, 2022, 12, 423.	1.3	17
59	Akt Kinase-Interacting Protein 1 Signals through CREB to Drive Diffuse Malignant Mesothelioma. Cancer Research, 2015, 75, 4188-4197.	0.4	16
60	Plasma membrane anchored nanosensor for quantifying endogenous production of H2O2 in living cells. Biosensors and Bioelectronics, 2021, 179, 113077.	5.3	16
61	Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation. Cancer Science, 2017, 108, 696-703.	1.7	15
62	A Bone Metastasis Model With Osteolytic and Osteoblastic Properties of Human Lung Cancer ACC-LC-319/bone2 in Natural Killer Cell-Depleted Severe Combined Immunodeficient Mice. Oncology Research, 2009, 17, 581-591.	0.6	15
63	E7080 Suppresses Hematogenous Multiple Organ Metastases of Lung Cancer Cells with Nonmutated Epidermal Growth Factor Receptor. Molecular Cancer Therapeutics, 2011, 10, 1218-1228.	1.9	14
64	Organâ€specific efficacy of <scp>HSP</scp>90 inhibitor in multipleâ€organ metastasis model of chemorefractory small cell lung cancer. International Journal of Cancer, 2016, 138, 1281-1289.	2.3	14
65	Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice. Molecular Cancer Therapeutics, 2019, 18, 947-956.	1.9	14
66	Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced nonâ€small cell lung cancer. Thoracic Cancer, 2019, 10, 526-532.	0.8	13
67	Impact of preexisting antinuclear antibodies on combined immunotherapy and chemotherapy in advanced non-small cell lung cancer patients. Medical Oncology, 2020, 37, 111.	1.2	13
68	Endocrinopathies Associated with Immune Checkpoint Inhibitor Cancer Treatment: A Review. Journal of Clinical Medicine, 2020, 9, 2033.	1.0	13
69	Inhibition of c-Jun N-terminal kinase signaling increased apoptosis and prevented the emergence of ALK-TKI-tolerant cells in ALK-rearranged non-small cell lung cancer. Cancer Letters, 2021, 522, 119-128.	3.2	13
70	HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features. Npj Precision Oncology, 2022, 6, 5.	2.3	13
71	Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma. Oncology Reports, 2014, 31, 1109-1115.	1.2	12
72	A case of aseptic meningitis without neck rigidity occurring in a metastatic melanoma patient treated with ipilimumab. European Journal of Dermatology, 2017, 27, 193-194.	0.3	12

#	Article	IF	Citations
73	Pulmonary carcinosarcoma showing an obvious response to pazopanib: a case report. BMC Pulmonary Medicine, 2018, 18, 193.	0.8	12
74	Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational study. Translational Lung Cancer Research, 2021, 10, 3582-3593.	1.3	12
75	Nicotine Induces Resistance to Erlotinib Therapy in Non-Small-Cell Lung Cancer Cells Treated with Serum from Human Patients. Cancers, 2019, 11, 282.	1.7	11
76	Phase I/II trial of biweekly docetaxel and cisplatin with concurrent thoracic radiation for stage III non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology, 2006, 58, 735-741.	1.1	10
77	Comparing three different anti-PD-L1 antibodies for immunohistochemical evaluation of small cell lung cancer. Lung Cancer, 2019, 137, 108-112.	0.9	10
78	Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment. Journal of Clinical Medicine, 2020, 9, 1762.	1.0	10
79	Impact of docetaxel plus ramucirumab in a secondâ€line setting after chemoimmunotherapy in patients with nonâ€smallâ€cell lung cancer: A retrospective study. Thoracic Cancer, 2022, 13, 173-181.	0.8	10
80	A novel potent inhibitor of inducible nitric oxide synthase, ONO-1714, reduces hyperoxic lung injury in mice. Respiratory Medicine, 2007, 101, 793-799.	1.3	9
81	Expression of Akt Kinase-Interacting Protein 1, a Scaffold Protein of the PI3K/PDK1/Akt Pathway, in Pancreatic Cancer. Pancreas, 2014, 43, 1093-1100.	0.5	9
82	Therapeutic activity of glycoengineered antiâ€<scp>GM</scp>2 antibodies against malignant pleural mesothelioma. Cancer Science, 2015, 106, 102-107.	1.7	9
83	Association of immune checkpoint inhibitors with respiratory infections: A review. Cancer Treatment Reviews, 2020, 90, 102109.	3.4	9
84	Prognostic impact of pleural effusion in EGFRâ€mutant nonâ€small cell lung cancer patients without brain metastasis. Thoracic Cancer, 2019, 10, 557-563.	0.8	8
85	Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation. Cancers, 2019, 11, 365.	1.7	8
86	Rationale and Design of a Phase II Trial of Osimertinib Combined With Bevacizumab in Patients With Untreated Epidermal Growth Factor Receptor-mutated Nonâ€“small-cell Lung Cancer and Malignant Pleural and/or Pericardial Effusion (SPIRAL II Study). Clinical Lung Cancer, 2019, 20, e402-e406.	1.1	8
87	Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study). Therapeutic Advances in Medical Oncology, 2020, 12, 175883592092784.	1.4	8
88	The Impact of VEGF Inhibition on Clinical Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy: A Retrospective Cohort Study. Frontiers in Oncology, 2021, 11, 663612.	1.3	8
89	Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib. Diagnostics, 2021, 11, 2170.	1.3	8
90	Combined chemotherapy with carboplatin plus irinotecan showed favorable efficacy in a patient with relapsed small cell carcinoma of the prostate complicated with meningeal carcinomatosis. International Journal of Clinical Oncology, 2009, 14, 468-472.	1.0	7

#	Article	IF	Citations
91	Metastatic renal cell carcinoma complicated with diffuse alveolar hemorrhage: a rare adverse effect of sunitinib. International Journal of Clinical Oncology, 2010, 15, 638-641.	1.0	7
92	Late-onset Pleural and Pericardial Effusion as Immune-related Adverse Events after 94 Cycles of Nivolumab. Internal Medicine, 2021, 60, 3585-3588.	0.3	7
93	A multicenter-retrospective study of non-small-cell lung carcinoma harboring uncommon epidermal growth factor receptor (EGFR) mutations: different subtypes of EGFR exon 19 deletion-insertions exhibit the clinical characteristics and prognosis of non-small cell lung carcinoma. Translational Lung Cancer Research, 2022, 11, 238-249.	1.3	7
94	Antiangiogenic therapies for malignant pleural mesothelioma. Frontiers in Bioscience - Landmark, 2011, 16, 740.	3.0	6
95	Treatment rationale and design of the SPIRAL study. Medicine (United States), 2018, 97, e11081.	0.4	6
96	Androgen replacement therapy for cancerâ€related symptoms in male: result of prospective randomized trial (ARTFORM study). Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 831-842.	2.9	6
97	Successful sequential treatment of refractory tumors caused by small cell carcinoma transformation and EGFR-T790M mutation diagnosed by repeated genetic testing in a patient with lung adenocarcinoma harboring epidermal growth factor receptor mutations: A case report. Respiratory Medicine Case Reports, 2018, 25, 261-263.	0.2	5
98	Nab-paclitaxel maintenance therapy following carboplatin + nab-paclitaxel combination therapy in chemotherapy naÃ¯ve patients with advanced non-small cell lung cancer: multicenter, open-label, single-arm phase II trial. Investigational New Drugs, 2018, 36, 903-910.	1.2	5
99	Treatment rationale and design of the RAMNITA study. Medicine (United States), 2018, 97, e11084.	0.4	5
100	Advanced Gâ€CSF â€producing nonâ€small cell lung cancerâ€not otherwise specified, with favourable response to pembrolizumab monotherapy. Respirology Case Reports, 2020, 8, e00625.	0.3	5
101	Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFRâ€T790M mutation in nonâ€small cell lung cancer cells. Cancer Medicine, 2022, 11, 944-955.	1.3	5
102	Phase I study of S-1 plus paclitaxel combination therapy as a first-line treatment in elderly patients with advanced non-small cell lung cancer. Investigational New Drugs, 2019, 37, 291-296.	1.2	4
103	Phase II Study on Biweekly Combination Therapy of Gemcitabine plus Carboplatin for the Treatment of Elderly Patients with Advanced Non-Small Cell Lung Cancer. Oncologist, 2020, 25, 208-e417.	1.9	4
104	Early discontinuation of induction therapy in chemoimmunotherapy as an effective alternative to the standard regimen in patients with non-small cell lung cancer: a retrospective study. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2437-2446.	1.2	4
105	TTF-1 and c-MYC-defined Phenotypes of Large Cell Neuroendocrine Carcinoma and Delta-like Protein 3 Expression for Treatment Selection. Applied Immunohistochemistry and Molecular Morphology, 2021, 29, 313-320.	0.6	4
106	The Impact of Immune-related Adverse Events on the Effect of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer. Japanese Journal of Lung Cancer, 2019, 59, 128-136.	0.0	4
107	Abstract PR7: Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor-resistance in EML4-ALK lung cancer cells. Clinical Cancer Research, 2012, 18, PR7-PR7.	3.2	4
108	A real-world study on the safety of the extended dosing schedule for nivolumab and pembrolizumab in patients with solid tumors. International Immunopharmacology, 2022, 108, 108775.	1.7	4

#	Article	IF	Citations
109	Efficacy and Safety of Programmed Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC: A Prospective Observational Study. JTO Clinical and Research Reports, 2022, 3, 100353.	0.6	4
110	Phase II Study of S-1 and Paclitaxel Combination Therapy in Patients with Previously Treated Non-Small Cell Lung Cancer. Oncologist, 2019, 24, 1033-e617.	1.9	3
111	Rationale and design of a phase II trial of osimertinib as first-line treatment for elderly patients with epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer (SPIRAL-0) Tj ETQq1 1 0.784314 rgBT /Overlock	1.4	3
112	A Phase II Study of Sâ€1 and Paclitaxel Combination Therapy as a Firstâ€Line Treatment in Elderly Patients with Advanced Nonâ€Small Cell Lung Cancer. Oncologist, 2019, 24, 459.	1.9	3
113	Respiratory complications of Stevens-Johnson syndrome (SJS): 3 cases of SJS-induced obstructive bronchiolitis. Allergology International, 2020, 69, 465-467.	1.4	3
114	Synchronous triple cancers of the pancreas, stomach, and cecum treated with S-1 followed by pancrelipase treatment of pancreatic exocrine insufficiency. JOP: Journal of the Pancreas, 2013, 14, 515-20.	1.5	3
115	The Quality of Life of Patients with Suspected Lung Cancer before and after Bronchoscopy and the Effect of Mirtazapine on the Depressive Status. Internal Medicine, 2020, 59, 1605-1610.	0.3	3
116	The Role of Percutaneous Needle Biopsy in Differentiation of Renal Tumors. Japanese Journal of Clinical Oncology, 2010, 40, 1081-1086.	0.6	2
117	In vivo imaging xenograft models for the evaluation of antiâ€brain tumor efficacy of targeted drugs. Cancer Medicine, 2017, 6, 2972-2983.	1.3	2
118	Androgen replacement therapy for cancer-related symptoms in male advanced cancer patients: study protocol for a randomised prospective trial (ARTFORM study). Journal of Medical Investigation, 2017, 64, 202-204.	0.2	2
119	Prognostic factors in older patients with wild-type epidermal growth factor receptor advanced non-small cell lung cancer: a multicenter retrospective study. Translational Lung Cancer Research, 2021, 10, 193-201.	1.3	2
120	HGF-MET in Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer. Current Signal Transduction Therapy, 2011, 6, 228-233.	0.3	2
121	Cancer of Unknown Primary Site in which Tumor Marker-Oriented Chemotherapy was Effective and Pancreatic Cancer was Finally Confirmed at Autopsy. Internal Medicine, 2009, 48, 1651-1656.	0.3	1
122	Effective combined therapy with ramucirumab for advanced pulmonary pleomorphic carcinoma. Respirology Case Reports, 2018, 6, e00372.	0.3	1
123	The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations. BMC Cancer, 2018, 18, 1241.	1.1	1
124	Rationale and design of a phase II study to evaluate prophylactic treatment of dacomitinib-induced dermatologic adverse events in epidermal growth factor receptor-mutated advanced non-small cell lung cancer (SPIRAL-Daco study). Translational Lung Cancer Research, 2019, 8, 519-523.	1.3	1
125	Phase I/II Study of Docetaxel and S-1 in Previously-Treated Patients with Advanced Non-Small Cell Lung Cancer: LOGIK0408. Journal of Clinical Medicine, 2019, 8, 2196.	1.0	1
126	Diverse Receptor Tyrosine Kinase Phosphorylation in Urine-Derived Tubular Epithelial Cells from Autosomal Dominant Polycystic Kidney Disease Patients. Nephron, 2020, 144, 525-536.	0.9	1

#	Article	IF	Citations
127	Histone deacetylase inhibitor OBPâ€‘801 and amrubicin synergistically inhibit the growth of squamous cell lung carcinoma by inducing mitochondrial ASK1â€‘dependent apoptosis. International Journal of Oncology, 2020, 56, 848-856.	1.4	1
128	Abstract 1692: The impact of neutrophil/lymphocyte ratio as the predictive marker to anti-PD-1 antibody treatment in NSCLC patients. , 2018, , .		1
129	Impact of maintenance therapy following induction immunochemotherapy for untreated advanced non-small cell lung cancer patients. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2985-2994.	1.2	1
130	P1.03-032 In vivo Imaging Models for Preclinical Screening of Molecular Targeted Drugs against Brain Metastasis. Journal of Thoracic Oncology, 2017, 12, S561-S562.	0.5	0
131	An observational study of the epidermal growth factor receptor-tyrosine kinase inhibitor resistance mechanism in epidermal growth factor receptor gene mutation-positive non-small cell lung cancer. Medicine (United States), 2018, 97, e12660.	0.4	0
132	Randomized Phase II Study of Firstâ€Line Biweekly Gemcitabine and Carboplatin Versus Biweekly Gemcitabine and Carboplatin plus Maintenance Gemcitabine in Elderly Patients with Untreated Nonâ€Small Cell Lung Cancer: LOGIK0801. Oncologist, 2020, 25, e1146-e1157.	1.9	0
133	MO2-5 Impact of pre-treatment AXL expression on EGFR-TKI efficacy in EGFR-mutated non-small cell lung cancer patients. Annals of Oncology, 2021, 32, S295.	0.6	0
134	SY13-3 Novel therapeutic strategies for drug-tolerance in NSCLC with driver oncogenes. Annals of Oncology, 2021, 32, S258.	0.6	0
135	Abstract A178: Role of tumor and hostâ€derived HGF in drug resistance to EGFR inhibitors in EGFR activating mutationâ€positive lung cancer. , 2009, , .		0
136	Abstract 626: Therapeutic effect of HGF inhibitors against HGF-induced EGFR-TKI resistance in lung cancer harboringEGFRmutations. , 2010, , .		0
137	Abstract 629: Hepatocyte growth factor induces resistance to an irreversible epidermal growth factor receptor inhibitor inEGFR-T790M mutant lung cancer. , 2010, , .		0
138	Abstract 1730: Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs inEGFRmutant lung cancer. , 2011, , .		0
139	Abstract B21: E7050, a Met kinase inhibitor, reverses three different mechanisms of hepatocyte growth factor-induced resistance to tyrosine kinase inhibitors in EGFR mutant lung cancer cells. Clinical Cancer Research, 2012, 18, B21-B21.	3.2	0
140	Abstract 1896: Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer. , 2012, , .		0
141	Abstract 1907: Heat shock protein 90 inhibition overcomes hepatocyte growth factor-triggering resistance to EGFR tyrosine kinase inhibitors in EGFR mutant lung cancer by decreasing client protein expression and angiogenesis. , 2012, , .		0
142	Abstract 2762: Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations. , 2014, , .		0
143	Abstract 3555: Akt kinase-interacting protein1 as a potential therapeutics target in CREB1 signaling in malignant pleural mesothelioma. , 2015, , .		0
144	Abstract 4763: Targeted therapy by MET inhibitors against small-cell lung cancer with aberrant activation of HGF/MET pathway. , 2016, , .		0

#	Article	IF	Citations
145	Abstract 4661: Loss of LKB1 in NSCLC confers sensitivity to MEK inhibition by regulating activation of AKT-FOXO3 pathway. , 2016, , .		0
146	Two cases of primary malignant melanoma of the esophagus. Skin Cancer, 2017, 32, 6-11.	0.1	0
147	Abstract 5535: Effect of LKB1 activity on the sensitivity to PI3K/mTOR inhibitor in non-small-cell lung cancer. , 2017, , .		0
148	Abstract 2839: Notch3-dependent beta-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC. , 2018, , .		0
149	Abstract 5843: The efficacy of a histone deacetylase inhibitor in combination with a MEK inhibitor in lung cancer cells harboring RAS mutations. , 2018, , .		0
150	Abstract 4899: The impact of theEGFR-T790M mutation detection by re-biopsy in EGFR mutant NSCLC patients in the retrospective analysis. , 2019, , .		0
151	Abstract 3996: Search for prognosis prediction factors in treatment selection for elderly patients with EGFR negative advanced stage non-small cell lung cancer patients. , 2019, , .		0
152	Abstract 4036: The efficacy of immune checkpoint inhibitors in patients with EGFR mutated non small cell lung cancer in retrospective analysis. , 2019, , .		0
153	Abstract 4306: Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients. , 2020, , .		0
154	Abstract 313: AXL confers intrinsic resistance to osimertinib and the emergence of tolerant cells. , 2019, , .		0
155	Efficacy and safety of immuno-chemotherapy in patients with advanced non-small-cell lung cancer harboring oncogenic mutations: a multicenter retrospective study. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	0